Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Sponsor: Abbott Diagnostics Division
This observational or N/A phase trial investigates Acute Decompensated Heart Failure and Acute Kidney Injury and is currently completed. Abbott Diagnostics Division leads this study, which shows 14 recorded versions since 2010 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Feb 2024 — Jul 2024 [monthly]
Completed
-
Jan 2023 — Feb 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
▶ Show 9 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Aug 2017 — Mar 2018 [monthly]
Unknown Status NA
-
Jan 2017 — Aug 2017 [monthly]
Unknown Status NA
First recorded
Dec 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott Diagnostics Division
- Alere San Diego
- Alere, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Athens, Greece , Basel, Switzerland , Brooklyn, United States , Detroit, United States , Dublin, Ireland , Groningen, Netherlands , Kansas City, United States , Naples, Italy , Pisa, Italy , Richmond, United States and 2 more locations